m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01802)
Name
2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
Synonyms
CHEMBL233874; 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H14N4
InChI
1S/C18H14N4/c1-13-7-9-16(10-8-13)21-18-20-12-15(11-19)17(22-18)14-5-3-2-4-6-14/h2-10,12H,1H3,(H,20,21,22)
InChIKey
OBWJJSHWDHTFAP-UHFFFAOYSA-N
PubChem CID
44430881
TTD Drug ID
D0E9DI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 1 (CDK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [1], [2]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile. The Protein virilizer homolog (VIRMA) has potential in affecting the response of 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile through regulating the expression of Cyclin-dependent kinase 1 (CDK1). [2], [3]
References
Ref 1 CircMETTL3, upregulated in a m6A-dependent manner, promotes breast cancer progression. Int J Biol Sci. 2021 Mar 15;17(5):1178-1190. doi: 10.7150/ijbs.57783. eCollection 2021.
Ref 2 Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. doi: 10.1016/j.bmcl.2006.04.071. Epub 2006 May 6.
Ref 3 KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019 Aug;38(33):6123-6141. doi: 10.1038/s41388-019-0861-z. Epub 2019 Jul 8.